Teva Pharmaceutical's Profit Jumps 8% on Strong Copaxone Sales

MS therapy Copaxone once again saves the day for Teva despite only modest generic gains and weak rest of world sales in the fourth-quarter.

Feb 6, 2014 at 12:43PM

Branded and generic pharmaceutical company Teva Pharmaceutical (NYSE:TEVA) reported slow but steady growth this morning with its fourth-quarter earnings release, led once again by strength from its lead drug, Copaxone.

For the quarter, Teva reported revenue of $5.43 billion, up 3.4% from the year-ago period, as adjusted EPS expanded nearly 8% to $1.42.

The primary growth driver, as is the case nearly every quarter with Teva, was multiple sclerosis therapy Copaxone, which registered $1.14 billion in sales, up 8% from the $1.06 billion reported in Q4 2012. Sales of the drug actually decreased 2% in the U.S. to $805 million as oral MS competition picked up, while higher sales in Russia and Germany more than offset U.S.-based declines. As a reminder to investors, Copaxone will begin to see its first patents expire in the U.S. later this year, potentially opening the drug up to generic competition.

Parkinson's disease drug Azilect and chronic lymphocytic leukemia therapy Treanda were two other highlights, with revenue up 12% and 10%, respectively.

Teva's generics business produced a rather ho-hum quarter, with total sales growth of just 1%, aided by a 14% increase in generics revenue in the U.S. as key branded drugs such as Niaspan, Temodar, and Cymbalta came off patent, and hampered by a 14% decrease in rest of world sales which was due to lower sales in Russia and a nasty 12% negative effect from currency translation. Total revenue from generics comprised 50% of Teva's fourth-quarter revenue, down marginally from the 51% in the year-ago period.

Teva also reaffirmed its prior fiscal outlook for 2014 and declared a Q4 dividend of approximately $0.34 based on today's exchange rate, a 5% increase from its previous quarterly payout.


Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool recommends Teva Pharmaceutical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information